Bank Julius Baer & Co. Ltd, Zurich Sage Therapeutics, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 10, 2021	SELL	$70.65 - $96.76 $218,873 - $299,762	-3,098 Closed	0 $0
Q4 2020 Feb 24, 2021	SELL	$58.41 - $89.06 $1.67 Million - $2.55 Million	-28,639 Reduced 90.24%	3,098 $268,000
Q4 2020 Feb 12, 2021	SELL	$58.41 - $89.06 $109,927 - $167,610	-1,882 Reduced 5.6%	31,737 $268,000
Q3 2020 Nov 10, 2020	BUY	$41.13 - $62.45 $293,914 - $446,267	7,146 Added 26.99%	33,619 $2.06 Million
Q2 2020 Aug 12, 2020	BUY	$25.95 - $43.15 $686,974 - $1.14 Million	26,473 New	26,473 $1.1 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $307M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.